Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 7230032 Calcium blockers to treat proliferative vitreoretinopathy

Patent 7230032 was granted and assigned to Allergan, Inc. on June, 2007 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity

All edits

Edits on 16 Sep, 2023
"Add patent inventor(s)"
Golden AI profile picture
Golden AI
edited on 16 Sep, 2023
Edits made to:
Infobox (+1 properties)
Infobox
Patent Inventor Names
Evan B. Dreyer0
Edits on 1 Sep, 2023
"Add patent abstract"
Golden AI profile picture
Golden AI
edited on 1 Sep, 2023
Edits made to:
Article (+515 characters)
Article

Patent abstract

Glutamate causes migration and proliferation of retinal pigment epithelium and/or glial cells, and glutamate antagonists can prevent, treat or reduce retinal pigment epithelium and/or glial migration and the subsequent development of proliferative vitreoretinopathy. Avoidance or management of proliferative vitreoretinopathy can be achieved by administering to the patient a compound capable of reducing glutamate-induced retinal cell migration in a concentration effective to reduce such migration.

Edits on 24 May, 2023
"Remove website redirecting to Patent Public Search front page"
Golden AI profile picture
Golden AI
edited on 24 May, 2023
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
https://pdfpiw.uspto.gov/.piw?Docid=072300320
Edits on 22 May, 2023
"Remove leading 0 from patent number"
Golden AI profile picture
Golden AI
edited on 22 May, 2023
Edits made to:
Infobox (+1/-1 properties)
‌

US Patent 07230032 Calcium blockers to treat proliferative vitreoretinopathy US Patent 7230032 Calcium blockers to treat proliferative vitreoretinopathy

Infobox
Patent Number
072300320
Patent Number
72300320
Edits on 23 Sep, 2022
"Entity importer update"
Golden AI profile picture
Golden AI
edited on 23 Sep, 2022
Infobox
Is a
Patent
Patent
0
Current Assignee
Allergan, Inc.
Allergan, Inc.
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
072300320
Date of Patent
June 12, 2007
0
Patent Application Number
104369020
Date Filed
May 12, 2003
0
Official Website
https://pdfpiw.uspto.gov/.piw?Docid=072300320
Patent Primary Examiner
‌
Zohreh A Fay
0
Edits on 15 Jun, 2022
"Entity importer update"
Golden AI profile picture
Golden AI
edited on 15 Jun, 2022
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
https://pdfpiw.uspto.gov/.piw?Docid=07230032
Edits on 21 Nov, 2021
"Created via: Entity Importer"
Golden AI profile picture
Golden AI
created this topic on 21 Nov, 2021
Edits made to:
Infobox (+8 properties)
‌

 US Patent 07230032 Calcium blockers to treat proliferative vitreoretinopathy

Infobox
Is a
Patent
Patent
Current assignee
Allergan, Inc.
Allergan, Inc.
Patent jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent number
07230032
Date of patent
June 12, 2007
Patent application number
10436902
Date Filed
May 12, 2003
Patent primary examiner
‌
Zohreh A Fay

Find more entities like US Patent 7230032 Calcium blockers to treat proliferative vitreoretinopathy

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.